Table 4.

Differences in BMD according to CYP3A4, CYP3A5 and UGT1A4 polymorphisms during treatment with anastrozole.

CYP3A4	wt/wt (n = 74)	wt/CYP3A4*1B (n = 5)	p *
BMD L1–L4	1.02 (0.91–1.15)	1.02 (0.99–1.07)	0.98
BMD total hip	0.89 (0.83–0.97)	1.03 (0.87–1.04)	0.15
BMD femoral neck	0.84 (0.77–0.90)	0.93 (0.76–0.94)	0.95
CYP3A5	CYP3A5*3/CYP3A5*3 (n = 70)	wt/CYP3A5*3 (n = 9)
BMD L1–L4	1.02 (0.91–1.14)	1.07 (0.99–1.15)	0.33
BMD total hip	0.89 (0.84–0.98)	0.91 (0.78–1.0)	0.78
BMD femoral neck	0.84 (0.77–0.90)	0.80 (0.76–0.94)	0.75
UGT1A4	wt/wt (n = 56)	wt/UGT1A4*2 (n = 3)
BMD L1–L4	1.03 (0.92–1.15)	1.13 (0.82–1.15)	0.95
BMD total hip	0.91 (0.84–1.0)	0.88 (0.75–1.06)	0.78
BMD femoral neck	0.85 (0.78–0.92)	0.81 (0.75–0.96)	0.70

* Mann–Whitney U test.